Search results for "Adverse reaction"

showing 10 items of 115 documents

A New Method for Revision of Encapsulated Blebs after Trabeculectomy: Combination of Standard Bleb Needling with Transconjunctival Scleral Flap Sutur…

2016

Purpose A simple needling procedure is the standard method for restoring the function of an encapsulated bleb after trabeculectomy. However, postoperative hypotony represents a possible hazard. This study describes a new surgical approach for treating encapsulated blebs with reduced risk of early postoperative hypotony: bleb needling combined with transconjunctival sutures tightening the scleral flap directly. Methods The study included two groups of 23 patients with failing bleb following trabeculectomy: “Group 1” underwent simple needling revision of the filtering bleb and served as a control group, while “Group 2” received needling revision with additional transconjunctival scleral flap …

MaleIntraocular pressureEye Diseasesgenetic structuresmedicine.medical_treatmentlcsh:MedicineGlaucomaOcular HypotensionPathology and Laboratory MedicineVascular MedicineSurgical FlapsCorneaBlisterPostoperative Complications0302 clinical medicineMedicine and Health SciencesGlaucoma surgeryTrabeculectomylcsh:ScienceDry needlingMultidisciplinaryOphthalmic ProceduresMiddle AgedScleramedicine.anatomical_structureFemaleAnatomyScleraResearch Articlemedicine.medical_specialtyOcular AnatomySurgical and Invasive Medical ProceduresHemorrhageTrabeculectomy03 medical and health sciencesSigns and SymptomsMusculoskeletal System ProceduresAdverse ReactionsOcular SystemDiagnostic MedicineOphthalmologymedicineHumansBleb (cell biology)Intraocular PressureAgedOcular HypotensionPharmacologybusiness.industrylcsh:RBiology and Life SciencesGlaucomamedicine.diseaseeye diseasesSurgeryOphthalmology030221 ophthalmology & optometrylcsh:Qsense organsbusiness030217 neurology & neurosurgeryPLOS ONE
researchProduct

Medical treatment and medical side effects in urinary incontinence in the elderly

1998

MaleNephrologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsIncontinencia urinariaUrinary Incontinence StressUrologyUrinary BladderUrinary incontinenceCentral nervous system diseaseInternal medicinemedicineHumansProstatismProstate diseaseAgedMedical treatmentbusiness.industryAge FactorsMuscle Smoothmedicine.diseaseSurgeryUrinary IncontinencePhysical therapyFemalemedicine.symptombusinessWorld Journal of Urology
researchProduct

A Model‐Based Workflow to Benchmark the Clinical Cholestasis Risk of Drugs

2021

We present a generic workflow combining physiology-based computational modeling and in vitro data to assess the clinical cholestatic risk of different drugs systematically. Changes in expression levels of genes involved in the enterohepatic circulation of bile acids were obtained from an in vitro assay mimicking 14 days of repeated drug administration for 10 marketed drugs. These changes in gene expression over time were contextualized in a physiology-based bile acid model of glycochenodeoxycholic acid. The simulated drug-induced response in bile acid concentrations was then scaled with the applied drug doses to calculate the cholestatic potential for each compound. A ranking of the cholest…

MalePHARMACOKINETICSAZATHIOPRINEAzathioprineBioinformatics030226 pharmacology & pharmacyWorkflowchemistry.chemical_compound0302 clinical medicinePARACETAMOLPharmacology (medical)Enterohepatic circulationmedia_common0303 health sciencesCholestasisBile acidMiddle Aged3. Good healthBenchmarkingLiverPharmaceutical PreparationsSINGLEDrug developmentFemaleVALPROATEmedicine.drugAdultDrugDrug-Related Side Effects and Adverse ReactionsDICLOFENAC SODIUMmedicine.drug_classmedia_common.quotation_subjectModels BiologicalYoung Adult03 medical and health sciencesCholestasisPharmacokineticsSpheroids CellularmedicineGlycochenodeoxycholic acidAnimalsHumansddc:610030304 developmental biologyPharmacologybusiness.industrymedicine.diseasechemistryACETAMINOPHENbusinessClinical Pharmacology & Therapeutics
researchProduct

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

2015

Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatmen…

MalePredictive Value of TestGastroenterologyCohort StudiesAntineoplastic AgentProspective StudiesProspective cohort studyMultivariate AnalysiLiver NeoplasmsHepatitis CMiddle AgedSorafenibItalyLiver NeoplasmHepatocellular carcinomaFemaleSurvival Analysimedicine.drugHumanSorafenibNiacinamidePhenylurea Compoundmedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsSettore MED/12 - GASTROENTEROLOGIAReproducibility of ResultAntineoplastic AgentsRisk AssessmentPredictive Value of TestsInternal medicinemedicineHumansNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingNeoplasm InvasiveneAnalysis of VarianceHepatologyPerformance statusbusiness.industryPhenylurea CompoundsPatient SelectionCarcinomaSettore MED/09 - MEDICINA INTERNAReproducibility of ResultsHepatocellularHepatologymedicine.diseaseSurvival AnalysisSurgeryDiscontinuationProspective StudieWithholding TreatmentMultivariate AnalysisCohort StudiebusinessDrug-Related Side Effects and Adverse Reaction
researchProduct

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

2017

AbstractPatients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongo…

MaleRiskmedicine.medical_specialtypulmonary embolismDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentHemorrhageintermediate risk030204 cardiovascular system & hematologyDabigatran03 medical and health sciencesYoung Adult0302 clinical medicineRecurrenceInternal medicineGermanymedicineHumansdabigatran030212 general & internal medicineProspective StudiesProspective cohort studySurvival analysisvenous thromboembolism recurrencebusiness.industryHeparinAnticoagulantsHematologyThrombolysisHeparinReference Standardsmedicine.diseaseThrombosisSurvival Analysis3. Good healthPulmonary embolismright ventricular functionRegimenTreatment OutcomeResearch Designmajor bleedingAcute Diseasedabigatran; intermediate risk; major bleeding; pulmonary embolism; right ventricular function; venous thromboembolism recurrenceFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

Risk of bleeding related to selective and non-selective serotonergic antidepressants: a case/non-case approach using data from two pharmacovigilance …

2014

There is increasing evidence for an association between treatment with selective serotonin reuptake inhibitors (SSRI) and an increased risk of bleeding events. The most important underlying mechanism appears to be inhibition of serotonin uptake in platelets, an effect that is also present in antidepressants with non-selective serotonin-reuptake inhibition (NSRI). Accordingly, also NSRI may be associated with an increased risk of bleeding. However, there is little data in this regard.Based on data (spontaneous reports of adverse drug reactions) from 2 pharmacovigilance databases (WHO-database/Vigibase™; BfArM/AkdÄ-database in Germany) we used a case/non-case approach and calculated reporting…

MaleSerotonin uptakeDatabases FactualDrug-Related Side Effects and Adverse ReactionsVenlafaxineHemorrhageSerotonergiccomputer.software_genrePharmacovigilanceDiclofenacSerotonin AgentsSerotonin AgentsGermanyPharmacovigilanceMedicineHumansPharmacology (medical)Databasebusiness.industryDepressionGeneral MedicineOdds ratioAntidepressive AgentsPsychiatry and Mental healthFemalebusinessReuptake inhibitorcomputermedicine.drugPharmacopsychiatry
researchProduct

Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano.

2012

Background The Bolivian northern Altiplano is characterized by a high prevalence of Fasciola hepatica infection. In order to assess the feasibility, safety and efficacy of large-scale administration of triclabendazole as an appropriate public health measure to control morbidity associated with fascioliasis, a pilot intervention was implemented in 2008. Materials and Methods Schoolchildren from an endemic community were screened for fascioliasis and treated with a single administration of triclabendazole (10 mg/kg). Interviews to assess the occurrence of adverse events were conducted on treatment day, one week later, and one month after treatment. Further parasitological screenings were perf…

MaleVeterinary medicineEndemic DiseasesNon-Clinical Medicinemedicine.medical_treatmentRC955-962Arctic medicine. Tropical medicineMedicineChildAnthelminticsbiologyTreatment OutcomeInfectious DiseasesTriclabendazoleChild PreschoolMedicineFemalePublic HealthPublic aspects of medicineRA1-1270After treatmentResearch Articlemedicine.drugSingle administrationBoliviaFascioliasismedicine.medical_specialtyAdolescentDrug-Related Side Effects and Adverse ReactionsChemopreventionInterviews as TopicInternal medicineparasitic diseasesAnimalsHumansFasciola hepaticaAdverse effectTriclabendazoleTreatment GuidelinesChemotherapyHealth Care Policybusiness.industryPublic healthPublic Health Environmental and Occupational HealthDrug PolicyFasciola hepaticabiology.organism_classificationParasitologyBenzimidazolesPreventive MedicinebusinessPLoS Neglected Tropical Diseases
researchProduct

Lethal Anaphylactic Reaction to Intravenous Gelatin in the Course of Surgery

2016

Plasma volume expanders (PVEs) are widely used to increase circulating blood volume. Gelatins used as PVEs are heterogeneous mixtures of polypeptides, usually prepared by hydrolysis of bovine collagen containing large amounts of proline and hydroxyproline residues. It has been shown that gelatins can cause anaphylactic reactions. We describe the case of a 73-year-old man who during surgery for intestinal obstruction presented a lethal anaphylactic reaction after the administration of a PVE containing gelatin lysate. The reaction occurred 10 minutes after the start of plasma expander infusion. Then, patient became comatose, and he died without awakening after 76 days. Necroptic aspects and h…

Malemedicine.medical_specialtyBovine collagenfood.ingredientPlasma SubstitutesBlood volumeAdministration IntravenouPlasma expanderGelatinDrug Hypersensitivity03 medical and health sciencesHydroxyprolinechemistry.chemical_compoundFatal Outcome0302 clinical medicinefoodSettore MED/43 - Medicina LegaleAnaphylaximedicineHumansPharmacology (medical)030212 general & internal medicineComaAdverse effectAnaphylaxisAgedPharmacologyIntravenous Gelatinbusiness.industryPlasma SubstituteAnaphylactic reactionAnaphylactic reactionsGeneral MedicineAdverse reactionPlasma expanderSurgeryLethal Anaphylactic Reaction030228 respiratory systemchemistryPlasma volume expandersAnesthesiaGelatinAdministration IntravenousPlasma volume expanders Lethal Anaphylactic Reaction Intravenous GelatinbusinessIntestinal ObstructionHumanAmerican Journal of Therapeutics
researchProduct

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).

2012

To prospectively compare the renal safety of meglumine gadoterate (Gd-DOTA)-enhanced magnetic resonance imaging (MRI) to a control group (unenhanced MRI) in high-risk patients.Patients with chronic kidney disease (CKD) scheduled for MRI procedures were screened. The primary endpoint was the percentage of patients with an elevation of serum creatinine levels, measured 72 ± 24 h after the MRI procedure, by at least 25 % or 44.2 μmol/l (0.5 mg/dl) from baseline. A non-inferiority margin of the between-group difference was set at -15 % for statistical analysis of the primary endpoint. Main secondary endpoints were the variation in serum creatinine and eGFR values between baseline and 72 ± 24 h …

Malemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsContrast MediaNephrogenic Fibrosing DermopathyHeterocyclic CompoundsRisk FactorsOrganometallic CompoundsPrevalenceMedicineHumansRadiology Nuclear Medicine and imagingRenal Insufficiency ChronicneoplasmsNeuroradiologyAgedmedicine.diagnostic_testMegluminebusiness.industryAcute kidney injuryMagnetic resonance imagingInterventional radiologyGeneral MedicineAcute Kidney Injurymedicine.diseaseMagnetic Resonance ImagingEuropeTreatment OutcomeRadiology Nuclear Medicine and imagingNephrogenic systemic fibrosisAngiographyFemaleRadiologybusinessmedicine.drugKidney diseaseEuropean radiology
researchProduct

Outcomes of Patients Hospitalized with Community-Acquired, Health Care-Associated, and Hospital-Acquired Pneumonia

2009

Background Traditionally, pneumonia has been classified as either community- or hospital-acquired. Although only limited data are available, health care-associated pneumonia has been recently proposed as a new category of respiratory infection. "Health care-associated pneumonia" refers to pneumonia in patients who have recently been hospitalized, had hemodialysis, or received intravenous chemotherapy or reside in a nursing home or long-term care facility. Objective To ascertain the epidemiology and outcome of community-acquired, health care-associated, and hospital-acquired pneumonia in adults hospitalized in internal medicine wards. Design Multicenter, prospective observational study. Sett…

Malemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHospital-acquired pneumoniaCommunity-acquired pneumoniaRenal DialysisRisk FactorsInternal medicineOutcome Assessment Health CareEpidemiologyPneumonia BacterialInternal MedicinemedicineHumansProspective StudiesIntensive care medicineAgedCross Infectionmedicine.diagnostic_testbusiness.industryMortality rateRespiratory infectionGeneral MedicineOdds ratiomedicine.diseaseLong-Term CareAnti-Bacterial AgentsNursing HomesCommunity-Acquired InfectionsPneumoniaItalyFemaleChest radiographbusinessDelivery of Health Care
researchProduct